Accuray

Accuray, founded in 1990, is a leader in the medical devices and equipment industry, specializing in advanced radiation oncology systems. The company develops innovative hardware and software solutions designed to deliver precise cancer treatment. By integrating sophisticated imaging, adaptive treatment planning, and robotic delivery technology, Accuray enables clinicians to target tumors with high accuracy while minimizing exposure to healthy tissue. The firm maintains a global operational footprint, supporting hospitals and specialized cancer treatment centers worldwide. Learn about Accuray's global headquarters for more information on their geographic presence.

With a workforce of 500-1,000 employees, Accuray manages complex manufacturing and R&D operations to support its clinical platforms. The company’s portfolio includes advanced radiotherapy and radiosurgery systems that allow medical teams to adjust therapy in real-time based on anatomical changes. This adaptive capability is critical for maintaining treatment efficacy across various cancer types, including brain, head-and-neck, thoracic, and abdominal malignancies. Meet Accuray's team to learn about the leadership and technical expertise driving their product development strategy.

Publicly traded under the ticker NASDAQ: ARAY, the company demonstrates a robust market position within the oncology sector. Accuray reported annual revenue of $428.6M, reflecting its sustained impact on clinical outcomes and healthcare infrastructure. The organization continues to invest in technological integration to address the evolving needs of oncology providers. Explore financial highlights to review detailed metrics and funding history, including recent debt financing activities. Accuray remains committed to expanding treatment capabilities for patients globally through its specialized medical device portfolio.